Anfield Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Anfield Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.6K	Buy	+200	New	+$25K	0.01%	321

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Anfield Capital Management's XBI Position: Q1 2026 in Review

Anfield Capital Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 200 shares worth $25.6K. The stake represents 0.01% of the portfolio and ranks #321 among its holdings.

816 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Anfield Capital Management held 200 shares of State Street SPDR S&P Biotech ETF worth $25.6K as of Q1 2026.
State Street SPDR S&P Biotech ETF was a new Anfield Capital Management position in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of Anfield Capital Management's portfolio in Q1 2026, its #321 holding.
816 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.